Regulus Therapeutics, a biopharmaceutical company focused on medicines targeting microRNAs, has appointed Bruce Carter, Ph.D., to its board of directors.

Carter has over 20 years of pharmaceutical and biotech drug development experience and previously served as CEO of Zymogenetics and chief scientific officer for Novo Nordisk. He currently serves as an independent member of the board of directors of Immune Design, a privately held biotech company in Seattle; chairman of the board of the TB Alliance, a worldwide nonprofit organization based in New York City; chairman of the board of Xencor in Pasadena, Calif.; board member for Dr. Reddy in Hyderabad, India; and board member of QLT of Vancouver, B.C., Canada.